Hearn Jay Cho
Impact in
- Hematology top 1%
- Multiple Myeloma Research and Treatments
- Immunology top 2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune Response and Inflammation
Papers in
- Hematology 112
- Multiple Myeloma Research and Treatments 110
- Oncology 60
- CAR-T cell therapy research 23
- Cancer Treatment and Pharmacology 12
- Peptidase Inhibition and Analysis 11
- Co-authors
- Carl NathanRichard A. MumfordAihao DingTerry D. LeeJimmy CalaycayQ W XieKristine M. SwiderekSundar Jagannath
- Journals
- Blood (70 papers)Journal of Clinical Oncology (8 papers)Blood Advances (4 papers)Clinical Cancer Research (3 papers)Cancer Research (3 papers)
- Partner nations
- United StatesCanadaSwitzerland
In The Last Decade
Hearn Jay Cho
131 papers receiving 3.9k citations
Hit Papers
Peers
Comparison fields: 5 of 138
- Hematology 1.1k
- Immunology 1.3k
- Biochemistry 327
- Physiology 1.1k
- Oncology 971
Countries citing papers authored by Hearn Jay Cho
This map shows the geographic impact of Hearn Jay Cho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hearn Jay Cho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hearn Jay Cho more than expected).
Fields of papers citing papers by Hearn Jay Cho
This network shows the impact of papers produced by Hearn Jay Cho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hearn Jay Cho. The network helps show where Hearn Jay Cho may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hearn Jay Cho, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 5 | |
| 3 | 2023 | 4 | |
| 4 | 2023 | 0 | |
| 5 | 2023 | 0 | |
| 6 | 2023 | 56 | |
| 7 | 2022 | 11 | |
| 8 | 2022 | 14 | |
| 9 | 2021 | 18 | |
| 10 | 2021 | 6 | |
| 11 | 2021 | 1 | |
| 12 | 2020 | 1 | |
| 13 | 2019 | 59 | |
| 14 | 2018 | 3 | |
| 15 | 2018 | 8 | |
| 16 | 2017 | 3 | |
| 17 | 2017 | 2 | |
| 18 | 2016 | 27 | |
| 19 | 2013 | 3 | |
| 20 | 2011 | 79 |
About Hearn Jay Cho
Hearn Jay Cho is a scholar working on Hematology, Oncology, Immunology, Genetics and Molecular Biology, having authored 140 papers that have together received 4.0k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (110 papers), Protein Degradation and Inhibitors (35 papers), Immunotherapy and Immune Responses (34 papers), CAR-T cell therapy research (23 papers), Monoclonal and Polyclonal Antibodies Research (15 papers), Chronic Lymphocytic Leukemia Research (12 papers), Cancer Treatment and Pharmacology (12 papers) and Peptidase Inhibition and Analysis (11 papers). The work is most often cited by research in Hematology (1.1k citations), Immunology (1.3k citations), Biochemistry (327 citations), Physiology (1.1k citations) and Oncology (971 citations). Hearn Jay Cho has collaborated with scholars based in United States, Canada and Switzerland. Frequent co-authors include Carl Nathan, Richard A. Mumford, Aihao Ding, Terry D. Lee, Jimmy Calaycay, Q W Xie, Kristine M. Swiderek, Sundar Jagannath, Ajai Chari and Samir Parekh. Their work appears in journals such as Blood, Journal of Clinical Oncology, Blood Advances, Clinical Cancer Research and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.